Empasiprubart for Teenage CIDP: Dose and Safety Study
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new medicine called empasiprubart in teenagers ages 12–17 with CIDP, a rare nerve disease that causes weakness and numbness. Researchers want to find the right dose and see if it safely reduces symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old
- You have been diagnosed with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) confirmed by nerve tests
- Your CIDP is one of these types: typical, motor-predominant, multifocal (Lewis-Sumner), focal, or distal
- You do not have sensory-only CIDP
- You have not previously taken long-acting immune-modifying drugs for CIDP
- You do not have other autoimmune diseases that would interfere with assessing your CIDP or put you at risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
This study tests a new medicine called empasiprubart in adults with multifocal motor neuropathy (MMN), a rare condition affecting nerve function. The trial uses ultrasound to see if the medicine can help reduce nerve thickening and improve symptoms.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.